GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Lipomics and Duke Collaborate on Pharmacometabolomic Marker Research

  • Lipomics Technologies and Duke University signed a deal to identify pharmacometabolomic markers in various clinical areas. Initial research will focus on CNS disorders such as schizophrenia and depression and cardiovascular diseases in terms of response to statins.

    Under this two-year agreement, Lipomics will provide Duke technology and services for biomarker research, validation, and analysis. In return, Lipomics has the option to license diagnostic rights on all such markers developed.

    Lipomics’ platform and technologies relating to lipid profiles and data transfer and interpretation services will be used by the Duke scientists.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?